Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
Want to see CTNM full AI Analyst Report?
CTNM Stock Chart & Stats
$13.53
-$0.71(-5.12%)
At close: 4:00 PM EST
$13.53
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$3.57 - $16.33
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$422.47M
Enterprise Value$491.14M
Total Cash (Recent Filing)$246.33M
Total Debt (Recent Filing)$6.95M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding32,723,877
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.03K
Enterprise Value/Ebitda-7.59
Forecast
1Y Price Target
$21.20Price Target Upside56.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$8.26M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage and substantial equity provide durable financial flexibility to fund multi-quarter clinical programs, absorb setbacks, and negotiate partnerships without immediate solvency pressure. This cushion supports strategic optionality over several quarters of development.
Clinical Progress (PIPE-791 Phase 1b)Positive Phase 1b topline data for PIPE-791 with favorable safety and exploratory efficacy de-risks a lead program and strengthens the R&D pipeline. Durable clinical progress improves partnering and licensing prospects and underpins longer-term development strategy if replicated in later studies.
Access To Capital (ATM Expansion)An expanded $100M ATM facility provides an on-demand equity financing tool to extend runway and pace trials. This structural financing flexibility reduces acute liquidity risk and allows management to opportunistically fund development over multiple quarters.
Bears Say
No Revenue And Large Operating LossesThe company remains pre-revenue with substantial operating losses, indicating long-term reliance on successful clinical outcomes to generate revenue. Persistent negative operating performance elevates funding needs and increases strategic risk if clinical or regulatory setbacks occur.
Ongoing Cash BurnSustained negative operating and free cash flow reflect structural cash consumption to progress R&D. This creates recurring dependency on external capital, increasing dilution risk and constraining multi-year R&D planning if market access tightens or financing terms worsen.
Historical Balance-Sheet VolatilityPrior episodes of negative equity and elevated debt in 2023 demonstrate past financing strain, signaling vulnerability to capital-market shocks. That history indicates a structural risk that adverse trial outcomes or market dislocations could force dilutive raises or restructuring, disrupting strategy.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $3.57 and its highest was $16.33 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $422.47M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Aug 18, 2026 which is in 67 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.532 by $0.142.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,723,877 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.532. Following the earnings report the stock price went up 3.822%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (56.69% Upside)
$21.20 (56.69% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
-27.09%
Trailing 12-Months
Asset Growth
31.82%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This compound is currently being investigated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Additionally, Contineum is developing PIPE-307, a novel small molecule functioning as a selective inhibitor of the muscarinic type 1 M1 receptor, intended for the management of depression and relapse-remitting MS. Another asset in their pipeline is CTX-343, an LPA1R antagonist with activity restricted to the periphery. Founded in 2009, this San Diego, California-headquartered organization was formerly known as Pipeline Therapeutics, Inc. before officially changing its name to Contineum Therapeutics, Inc. in November 2023.
CTNM Stock 12 Month Forecast
Average Price Target
$21.20
▲(56.69% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.50% Insiders
8.81% Mutual Funds
49.93% Other Institutional Investors
35.45% Public Companies and
Individual Investors